Leone Patterson, currently president and chief financial officer, has served in various executive positions at Adverum. Previously, she served as chief executive officer and as a director from 2018 to 2020. She joined the Company as chief financial officer in June 2016. Under Ms. Patterson’s leadership as chief executive officer, she led Adverum from preclinical stage to a clinical-stage Company by advancing its lead gene therapy product candidate, ADVM-022 (AAV.7m8). through two clinical trials currently underway for the treatment of patients with age-related macular degeneration and diabetic macular edema.
Ms. Patterson has over 20 years of experience in the biotechnology industry. Previously, Ms. Patterson served as the chief financial officer of Diadexus, Inc. Earlier, Ms. Patterson was chief financial officer of Transcept Pharmaceuticals, Inc. until it was acquired by Paratek Pharmaceuticals Inc. Previously, Ms. Patterson served as vice president and global corporate controller of NetApp, Inc. Earlier in her career, Ms. Patterson was vice president of finance at Exelixis, Inc. and vice president of global business planning and analysis at Novartis AG after the acquisition of Chiron. Ms. Patterson began her career at KPMG working in the firm’s audit practice. Ms. Patterson earned a B.S. in Business Administration and Accounting from Chapman University and an Executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status). Ms. Patterson currently serves on the board of directors for Nkarta, Inc. and Eliem Therapeutics.